# CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

> **NCT06305910** · PHASE1 · RECRUITING · sponsor: **OX2 Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Midline Glioma, H3 K27M-Mutant
- Recurrent High Grade Glioma

## Interventions

- **DRUG:** Treatment with CD200AR-L

## Key facts

- **NCT ID:** NCT06305910
- **Lead sponsor:** OX2 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2025-09-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305910, "CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06305910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*